Loading…
Chinese CDMO that manufactures small-molecule active ingredients and intermediates for global pharma and biotech under contract.
Chinese CDMO that manufactures small-molecule active ingredients and intermediates for global pharma and biotech under contract.
Customers hire it first to develop the manufacturing process for a drug in trials, which can lead to long commercial supply contracts if the drug is approved, so orders build over several years. COVID-treatment work temporarily boosted its sales during the pandemic. It is listed in both Shenzhen and Hong Kong.
In one line: A China-based Cambrex/Lonza for small-molecule APIs.
Moat: narrow (process know-how, customer qualification, regulatory licence). FDA/EMA-audited plants and validated processes make switching a qualified program costly.
Headquarters: Tianjin, China · Founded: 1995 · Employees: 10,617
Size Asymchem Laboratories (Tianjin) (002821.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $8.07B, the 307th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥155.03 on 6 Nov 2026.
Performance Over six months the shares gained 23.5%, against +6.7% for the median peer and -16.4% for the China market (cap-weighted) — 8th highest of 21 in its peer set.
Growth Revenue grew 18.1% over the last twelve months (peer median +12.8%); the operating margin is 17.2% (peer median 13.8%).
Valuation It trades at 41.4× forward earnings against a peer median of 24.3× (4th most expensive of 15).
Capital Return on invested capital runs 1.6 points above its cost of capital (9.5% WACC).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥7.44B | CN¥6.64B | CN¥5.73B | CN¥7.78B | CN¥10.2B |
| Revenue growth | — | +16% | -26% | -24% | — |
| Gross profit | CN¥3.47B | CN¥2.64B | CN¥2.25B | CN¥3.83B | CN¥4.72B |
| EBITDA | n/a | CN¥1.61B | CN¥1.13B | CN¥2.70B | CN¥3.47B |
| Net income | CN¥1.18B | CN¥1.13B | CN¥949M | CN¥2.27B | CN¥3.30B |
| Free cash flow | -CN¥703M | CN¥330M | CN¥280M | CN¥2.51B | CN¥1.18B |
| Capital expenditure | CN¥1.84B | CN¥1.27B | CN¥1.13B | CN¥1.24B | CN¥2.15B |
| Total debt | CN¥689M | CN¥524M | CN¥475M | CN¥572M | CN¥585M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Asymchem Laboratories (Tianjin) 002821.SZ | $8.07B | +23% | +18% | 17% | 41.4× | n/a |
| WuXi AppTec 603259.SS | $67.0B | +34% | +32% | 43% | 18.1× | 7.8% |
| Porton Pharma Solutions 300363.SZ | $1.92B | +14% | +6% | -2% | n/a | 5.3% |
| Lonza LONN.SW | $55.4B | +39% | -11% | 25% | 36.1× | 15.0% |
| Siegfried SFZN.SW | $3.98B | -10% | +4% | 16% | 17.8× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002821.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -14.2% | +4.1% | 3rd lowest of 21 |
| 6-month return | +23.5% | +6.7% | 8th highest of 21 |
| Distance from 52-week high | -22.5% | -13.0% | 8th lowest of 21 |
| Revenue growth (TTM) | +18.1% | +12.8% | 9th highest of 21 |
| Operating margin | 17.2% | 13.8% | 7th highest of 20 |
| Forward P/E | 41.4× | 24.3× | 4th most expensive of 15 |
| ROIC minus cost of capital | +1.6 pp | +1.9 pp | 9th lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Asymchem Laboratories (Tianjin) 002821.SZ | China | $8.07B | +23% | +18% | 17% | 41.4× | n/a | n/a |
| Kyowa Kirin 4151.T | Japan | $8.05B | +4% | +10% | 24% | 15.6× | -6.1% | +9.3% |
| H. Lundbeck A/S HLUN-A.CO | Denmark | $8.02B | +47% | +9% | 27% | n/a | -9.1% | +6.6% |
| ALK-abello A/S ALK-B.CO | Denmark | $8.14B | -5% | +17% | 27% | 35.7× | 7.6% | +12.6% |
| Corcept Therapeutics CORT | United States | $7.96B | +39% | +30% | 12% | 16.4× | 24.9% | +16.6% |
| Shanghai Pharmaceuticals 601607.SS | China | $8.32B | -2% | +4% | 3% | 11.4× | -10.0% | +8.1% |
| Rhythm Pharmaceuticals RYTM | United States | $7.78B | +19% | +61% | -67% | n/a | n/a | n/a |
| Praxis Precision Medicines PRAX | United States | $7.75B | -16% | -100% | n/a | n/a | n/a | n/a |
| Glenmark Pharmaceuticals GLENMARK.NS | India | $7.73B | +9% | +33% | 20% | 32.0× | 20.0% | +9.4% |
| Alkermes Public ALKS | United States | $7.71B | +31% | +15% | 5% | n/a | 31.5% | +7.3% |
| Protagonist Therapeutics PTGX | United States | $8.54B | +33% | +35% | 21% | 48.4× | 47.5% | +10.0% |
| Grifols GRF.MC | Spain | $7.49B | +23% | 0% | 16% | 13.0× | 6.8% | +7.1% |
| Shanghai Fosun Pharmaceutical (Group) 2196.HK | Hong Kong | $8.69B | -10% | +10% | 6% | 10.4× | 20.5% | +5.8% |
| Cytokinetics CYTK | United States | $7.46B | -30% | -21% | -1,046% | n/a | n/a | n/a |
| Kiniksa Pharmaceuticals International KNSA | United States | $7.37B | +60% | +58% | 14% | 61.7× | 9.9% | +45.5% |
| Bachem BANB.SW | Switzerland | $7.32B | +3% | +5% | 19% | 33.1× | n/a | n/a |
| Huadong Medicine 000963.SZ | China | $7.29B | -17% | +2% | 9% | 14.0× | -2.7% | +5.3% |
| ImmunityBio IBRX | United States | $9.15B | +1% | +193% | -152% | n/a | n/a | n/a |
| TG Therapeutics TGTX | United States | $9.16B | +40% | +76% | 17% | 30.9× | 50.3% | +426.7% |
| Amneal Pharmaceuticals AMRX | United States | $7.01B | +53% | +9% | 17% | 17.7× | 15.2% | +8.7% |
| Madrigal Pharmaceuticals MDGL | United States | $9.28B | -22% | +93% | -11% | 79.5× | n/a | n/a |